vs
Side-by-side financial comparison of Labcorp (LH) and Texas Instruments (TXN). Click either name above to swap in a different company.
Texas Instruments is the larger business by last-quarter revenue ($4.8B vs $3.5B, roughly 1.4× Labcorp). Texas Instruments runs the higher net margin — 32.0% vs 4.7%, a 27.3% gap on every dollar of revenue. On growth, Texas Instruments posted the faster year-over-year revenue change (18.6% vs 5.6%). Texas Instruments produced more free cash flow last quarter ($1.4B vs $490.3M). Over the past eight quarters, Texas Instruments's revenue compounded faster (12.4% CAGR vs 5.2%).
Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.
Texas Instruments Incorporated (TI) is an American multinational semiconductor company headquartered in Dallas, Texas. It is one of the top 10 semiconductor companies worldwide based on sales volume. The company's focus is on developing analog chips and embedded processors, which account for more than 80% of its revenue. TI also produces digital light processing (DLP) technology and education technology products including calculators, microcontrollers, and multi-core processors.
LH vs TXN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.5B | $4.8B |
| Net Profit | $164.7M | $1.5B |
| Gross Margin | 28.2% | 58.0% |
| Operating Margin | 7.6% | 37.5% |
| Net Margin | 4.7% | 32.0% |
| Revenue YoY | 5.6% | 18.6% |
| Net Profit YoY | 14.9% | 31.0% |
| EPS (diluted) | $1.98 | $1.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $4.8B | ||
| Q4 25 | $3.5B | $4.4B | ||
| Q3 25 | $3.6B | $4.7B | ||
| Q2 25 | $3.5B | $4.4B | ||
| Q1 25 | $3.3B | $4.1B | ||
| Q4 24 | $3.3B | $4.0B | ||
| Q3 24 | $3.3B | $4.2B | ||
| Q2 24 | $3.2B | $3.8B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $164.7M | $1.2B | ||
| Q3 25 | $261.1M | $1.4B | ||
| Q2 25 | $237.9M | $1.3B | ||
| Q1 25 | $212.8M | $1.2B | ||
| Q4 24 | $143.4M | $1.2B | ||
| Q3 24 | $169.3M | $1.4B | ||
| Q2 24 | $205.3M | $1.1B |
| Q1 26 | — | 58.0% | ||
| Q4 25 | 28.2% | 55.9% | ||
| Q3 25 | 28.8% | 57.4% | ||
| Q2 25 | 29.7% | 57.9% | ||
| Q1 25 | 28.3% | 56.8% | ||
| Q4 24 | 26.9% | 57.7% | ||
| Q3 24 | 27.6% | 59.6% | ||
| Q2 24 | 28.8% | 57.8% |
| Q1 26 | — | 37.5% | ||
| Q4 25 | 7.6% | 33.3% | ||
| Q3 25 | 11.1% | 35.1% | ||
| Q2 25 | 11.2% | 35.1% | ||
| Q1 25 | 9.7% | 32.5% | ||
| Q4 24 | 6.5% | 34.4% | ||
| Q3 24 | 7.7% | 37.4% | ||
| Q2 24 | 9.2% | 32.7% |
| Q1 26 | — | 32.0% | ||
| Q4 25 | 4.7% | 26.3% | ||
| Q3 25 | 7.3% | 28.8% | ||
| Q2 25 | 6.7% | 29.1% | ||
| Q1 25 | 6.4% | 29.0% | ||
| Q4 24 | 4.3% | 30.1% | ||
| Q3 24 | 5.2% | 32.8% | ||
| Q2 24 | 6.4% | 29.5% |
| Q1 26 | — | $1.68 | ||
| Q4 25 | $1.98 | $1.28 | ||
| Q3 25 | $3.12 | $1.48 | ||
| Q2 25 | $2.84 | $1.41 | ||
| Q1 25 | $2.52 | $1.28 | ||
| Q4 24 | $1.72 | $1.31 | ||
| Q3 24 | $2.00 | $1.47 | ||
| Q2 24 | $2.43 | $1.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $532.3M | $5.1B |
| Total DebtLower is stronger | — | $14.1B |
| Stockholders' EquityBook value | $8.6B | $16.8B |
| Total Assets | $18.4B | $34.4B |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.1B | ||
| Q4 25 | $532.3M | $4.9B | ||
| Q3 25 | $598.1M | $5.2B | ||
| Q2 25 | $647.3M | $5.4B | ||
| Q1 25 | $369.4M | $5.0B | ||
| Q4 24 | $1.5B | $7.6B | ||
| Q3 24 | $1.5B | $8.8B | ||
| Q2 24 | $265.1M | $9.7B |
| Q1 26 | — | $14.1B | ||
| Q4 25 | — | $14.0B | ||
| Q3 25 | — | $14.0B | ||
| Q2 25 | — | $14.0B | ||
| Q1 25 | — | $12.8B | ||
| Q4 24 | — | $13.6B | ||
| Q3 24 | — | $13.9B | ||
| Q2 24 | — | $13.9B |
| Q1 26 | — | $16.8B | ||
| Q4 25 | $8.6B | $16.3B | ||
| Q3 25 | $8.7B | $16.6B | ||
| Q2 25 | $8.5B | $16.4B | ||
| Q1 25 | $8.3B | $16.4B | ||
| Q4 24 | $8.1B | $16.9B | ||
| Q3 24 | $8.2B | $17.3B | ||
| Q2 24 | $8.0B | $17.2B |
| Q1 26 | — | $34.4B | ||
| Q4 25 | $18.4B | $34.6B | ||
| Q3 25 | $18.3B | $35.0B | ||
| Q2 25 | $18.1B | $34.9B | ||
| Q1 25 | $17.6B | $33.8B | ||
| Q4 24 | $18.4B | $35.5B | ||
| Q3 24 | $18.6B | $35.3B | ||
| Q2 24 | $16.7B | $35.0B |
| Q1 26 | — | 0.84× | ||
| Q4 25 | — | 0.86× | ||
| Q3 25 | — | 0.84× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.80× | ||
| Q3 24 | — | 0.80× | ||
| Q2 24 | — | 0.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $614.2M | — |
| Free Cash FlowOCF − Capex | $490.3M | $1.4B |
| FCF MarginFCF / Revenue | 13.9% | 29.0% |
| Capex IntensityCapex / Revenue | 3.5% | 14.0% |
| Cash ConversionOCF / Net Profit | 3.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $4.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $614.2M | $2.3B | ||
| Q3 25 | $387.2M | $2.2B | ||
| Q2 25 | $620.6M | $1.9B | ||
| Q1 25 | $18.5M | $849.0M | ||
| Q4 24 | $777.2M | $2.0B | ||
| Q3 24 | $277.3M | $1.7B | ||
| Q2 24 | $561.1M | $1.6B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $490.3M | $1.3B | ||
| Q3 25 | $280.5M | $993.0M | ||
| Q2 25 | $542.7M | $555.0M | ||
| Q1 25 | $-107.5M | $-274.0M | ||
| Q4 24 | $665.1M | $806.0M | ||
| Q3 24 | $161.5M | $416.0M | ||
| Q2 24 | $432.9M | $507.0M |
| Q1 26 | — | 29.0% | ||
| Q4 25 | 13.9% | 30.0% | ||
| Q3 25 | 7.9% | 20.9% | ||
| Q2 25 | 15.4% | 12.5% | ||
| Q1 25 | -3.2% | -6.7% | ||
| Q4 24 | 20.0% | 20.1% | ||
| Q3 24 | 4.9% | 10.0% | ||
| Q2 24 | 13.4% | 13.3% |
| Q1 26 | — | 14.0% | ||
| Q4 25 | 3.5% | 20.9% | ||
| Q3 25 | 3.0% | 25.2% | ||
| Q2 25 | 2.2% | 29.3% | ||
| Q1 25 | 3.8% | 27.6% | ||
| Q4 24 | 3.4% | 29.7% | ||
| Q3 24 | 3.5% | 31.7% | ||
| Q2 24 | 4.0% | 27.8% |
| Q1 26 | — | — | ||
| Q4 25 | 3.73× | 1.94× | ||
| Q3 25 | 1.48× | 1.61× | ||
| Q2 25 | 2.61× | 1.44× | ||
| Q1 25 | 0.09× | 0.72× | ||
| Q4 24 | 5.42× | 1.66× | ||
| Q3 24 | 1.64× | 1.27× | ||
| Q2 24 | 2.73× | 1.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
TXN
Segment breakdown not available.
